icon-folder.gif   Conference Reports for NATAP  
  EASL 45th Annual Meeting
April 14-18, 2010
Vienna, Austria
Back grey_arrow_rt.gif
Once-daily NS5A Inhibitor (BMS-790052) Plus Peginterferon-alpha-2a And Ribavirin Produces High Rates Of Extended Rapid Virologic Response In Treatment-naïve HCV-genotype 1 Subjects: Phase 2a Trial - Bristol-Myers Squibb Study AI444014
  Reported by Jules Levin
EASL, The International Liver Congress, Vienna, Austria, 2010 Apr 17, Late-breaker Presentation
S. Pol, G. Everson, R. Ghalib, V. Rustgi, C. Martorell, H. Tatum, J. Lim, C. Hezode, U. Diva, P.D. Yin, and R. Hindes

* Related to study regimen